INTRODUCTION: Mediastinal lymphadenopathy in patients with an extrathoracic malignancy is a common clinical scenario. Invasive sampling of intrathoracic lymph nodes may be performed by mediastinoscopy or endoscopic ultrasound-guided fine needle aspiration. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an alternative to mediastinoscopy and endoscopic ultrasound in patients with lung cancer and sarcoidosis. The utility of EBUS-TBNA in patients with extrathoracic malignancy was evaluated. METHODS: Consecutive patients who were suspected to have intrathoracic lymph node metastases from an extrathoracic malignancy underwent EBUS-TBNA. When EBUS-TBNA did not provide a specific diagnosis, patients underwent mediastinoscopy or clinical follow-up of at least 6 months duration. RESULTS: One hundred sixty-one patients meeting the inclusion criteria underwent EBUS-TBNA in five UK centers over a 3-year period. EBUS-TBNA diagnosed mediastinal or hilar metastases in 71 (44%) patients, new lung cancer in 20 (12%) patients, and sarcoidosis in 14 (9%) patients. The sensitivity, negative predictive value for malignancy, and overall accuracy for EBUS-TBNA were 87%, 73% and 88%, respectively. One hundred ten (68%) patients in the study had a final diagnosis of malignant intrathoracic lymphadenopathy. CONCLUSION: Because of the high prevalence of alternative diagnoses, pathological evaluation is important in patients with extrathoracic malignancy and suspected mediastinal or hilar lymph node metastases. EBUS-TBNA is a safe and sensitive technique and may be considered a first-line investigation in these patients.
INTRODUCTION: Mediastinal lymphadenopathy in patients with an extrathoracic malignancy is a common clinical scenario. Invasive sampling of intrathoracic lymph nodes may be performed by mediastinoscopy or endoscopic ultrasound-guided fine needle aspiration. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an alternative to mediastinoscopy and endoscopic ultrasound in patients with lung cancer and sarcoidosis. The utility of EBUS-TBNA in patients with extrathoracic malignancy was evaluated. METHODS: Consecutive patients who were suspected to have intrathoracic lymph node metastases from an extrathoracic malignancy underwent EBUS-TBNA. When EBUS-TBNA did not provide a specific diagnosis, patients underwent mediastinoscopy or clinical follow-up of at least 6 months duration. RESULTS: One hundred sixty-one patients meeting the inclusion criteria underwent EBUS-TBNA in five UK centers over a 3-year period. EBUS-TBNA diagnosed mediastinal or hilar metastases in 71 (44%) patients, new lung cancer in 20 (12%) patients, and sarcoidosis in 14 (9%) patients. The sensitivity, negative predictive value for malignancy, and overall accuracy for EBUS-TBNA were 87%, 73% and 88%, respectively. One hundred ten (68%) patients in the study had a final diagnosis of malignant intrathoracic lymphadenopathy. CONCLUSION: Because of the high prevalence of alternative diagnoses, pathological evaluation is important in patients with extrathoracic malignancy and suspected mediastinal or hilar lymph node metastases. EBUS-TBNA is a safe and sensitive technique and may be considered a first-line investigation in these patients.
Authors: Tidi Hassan; Anne Marie McLaughlin; Finbarr O'Connell; Noel Gibbons; Siobhan Nicholson; Joseph Keane Journal: Am J Respir Crit Care Med Date: 2011-01-01 Impact factor: 21.405
Authors: Anthony Lemaire; Ivana Nikolic; Thomas Petersen; Jack C Haney; Eric M Toloza; David H Harpole; Thomas A D'Amico; William R Burfeind Journal: Ann Thorac Surg Date: 2006-10 Impact factor: 4.330
Authors: Neal Navani; Helen L Booth; Gabrijela Kocjan; Mary Falzon; Arrigo Capitanio; James M Brown; Joanna C Porter; Sam M Janes Journal: Respirology Date: 2011-04 Impact factor: 6.424
Authors: Neal Navani; Matthew Nankivell; Parthiban Nadarajan; Stephen P Pereira; Gabrijela Kocjan; Sam M Janes Journal: Thorax Date: 2010-11-20 Impact factor: 9.139
Authors: Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen Journal: J Thorac Dis Date: 2015-09 Impact factor: 2.895
Authors: Christian Jenssen; Jouke Tabe Annema; Paul Clementsen; Xin-Wu Cui; Mathias Maximilian Borst; Christoph Frank Dietrich Journal: J Thorac Dis Date: 2015-10 Impact factor: 2.895
Authors: Christina R Bellinger; Deepankar Sharma; Jimmy Ruiz; Graham Parks; Travis Dotson; Edward F Haponik Journal: Lung Date: 2016-04-25 Impact factor: 2.584
Authors: Neal Navani; David R Lawrence; Shyam Kolvekar; Martin Hayward; Dorcas McAsey; Gabrijela Kocjan; Mary Falzon; Arrigo Capitanio; Penny Shaw; Stephen Morris; Rumana Z Omar; Sam M Janes Journal: Am J Respir Crit Care Med Date: 2012-05-31 Impact factor: 21.405
Authors: Jose Sanz-Santos; Beatriz Cirauqui; Estefania Sanchez; Felipe Andreo; Pere Serra; Eduard Monso; Eva Castellà; Mariona Llatjós; Miguel Mesa; Juan Ruiz-Manzano; Rafael Rosell Journal: Clin Exp Metastasis Date: 2012-11-30 Impact factor: 5.150